Wyeth Pharmaceuticals LLC Sustainability Profile
Wyeth Pharmaceuticals LLC, a prominent player in the global pharmaceutical industry, is headquartered in the United States. Founded in 1860, the company has a rich history marked by significant milestones, including its integration into the larger pharmaceutical landscape through mergers and acquisitions. Wyeth operates primarily in the biopharmaceutical sector, focusing on innovative treatments in areas such as immunology, oncology, and vaccines. The company is renowned for its core products, which include advanced biologics and specialty pharmaceuticals that address critical health needs. Wyeth's commitment to research and development has positioned it as a leader in the market, with notable achievements in vaccine development and chronic disease management. With a strong presence in North America and Europe, Wyeth Pharmaceuticals continues to make strides in improving patient outcomes and advancing healthcare solutions.
DitchCarbon Score
How does Wyeth Pharmaceuticals LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Wyeth Pharmaceuticals LLC's score of 84 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Wyeth Pharmaceuticals LLC, headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Pfizer Inc., which means that any climate commitments or emissions data may be inherited from its parent organisation. Pfizer Inc. has established various climate initiatives, including Science-Based Targets Initiative (SBTi) commitments, which are cascaded down to Wyeth Pharmaceuticals. However, specific reduction targets or achievements for Wyeth are not detailed in the available information. As part of its corporate family, Wyeth Pharmaceuticals is aligned with Pfizer's broader sustainability goals, which include commitments to reduce greenhouse gas emissions across all scopes. The absence of direct emissions data for Wyeth suggests a reliance on Pfizer's overarching strategies and targets to guide its climate actions. In summary, while Wyeth Pharmaceuticals LLC does not present specific emissions figures or reduction targets, it is positioned within Pfizer's climate framework, which aims to address carbon emissions and promote sustainability across its operations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 964,846,000 | - | - | - | - | - | - | - | 000,000,000 | - | - | - | 000,000,000 |
| Scope 2 | 883,814,000 | - | - | - | - | - | - | - | 000,000,000 | - | - | - | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 000,000,000 | 0,000,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 0,000,000,000 |
How Carbon Intensive is Wyeth Pharmaceuticals LLC's Industry?
How Carbon Intensive is Wyeth Pharmaceuticals LLC's Location?
Wyeth Pharmaceuticals LLC's Scope 3 Categories Breakdown
Wyeth Pharmaceuticals LLC's Scope 3 emissions, which increased significantly last year and increased by approximately 821% since 2019, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 77% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 79% of Scope 3 emissions.
Top Scope 3 Categories
Wyeth Pharmaceuticals LLC's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Wyeth Pharmaceuticals LLC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
